Romosozumab: from basic to clinical aspects

Area of Science:

• Bone biology and endocrinology.
• Pharmacology of monoclonal antibodies.

Background:

• The Wnt signaling pathway is crucial for bone formation.
• Sclerostin inhibits the Wnt pathway and is a target for increasing bone mass.

Discussion:

• Romosozumab, a sclerostin-targeting antibody, demonstrated anabolic effects in preclinical and early human studies.
• Observed increases in bone mineral density align with animal model findings.

Key Insights:

• Inhibiting sclerostin with romosozumab enhances bone formation.
• This antibody therapy leads to significant improvements in bone mineral density.

Outlook:

• Further large-scale studies with fracture endpoints are needed.
• Romosozumab may become a pivotal therapeutic agent for osteoporosis management.